Daniel Umbricht

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 54 publications

AUT00206, a novel and selective Kv3.1/3.2 channel modulator, restores cognitive dysfunction and negative symptoms in an animal model for schizophrenia symptomatology.

AUT00206, a novel and selective Kv3.1/3.2 channel modulator, restores cognitive dysfunction and negative symptoms in an animal model for schizophrenia symptomatology.

Journal: Journal of psychopharmacology (Oxford, England)

Published: August 12, 2026

Research agenda to advance anhedonia assessment, understanding and treatment: an ECNP-GALENOS expert meeting report.

Research agenda to advance anhedonia assessment, understanding and treatment: an ECNP-GALENOS expert meeting report.

Journal: BMJ mental health

Published: May 13, 2026

Linking human brain functional connectivity to underlying neurotransmission.

Linking human brain functional connectivity to underlying neurotransmission.

Journal: bioRxiv : the preprint server for biology

Published: May 07, 2026

A Phase 2b Multicenter Study to Evaluate Basmisanil as an Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia.

A Phase 2b Multicenter Study to Evaluate Basmisanil as an Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia.

Journal: The Journal of clinical psychiatry

Published: April 15, 2026

A novel psychedelic 5-HT2A receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer.

A novel psychedelic 5-HT2A receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer.

Journal: Journal of psychopharmacology (Oxford, England)

Published: October 16, 2025

Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve Them.

Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve Them.

Journal: The American journal of psychiatry

Published: October 08, 2025

Using the grip strength effort task to measure reward processing dysfunction in schizophrenia and major depressive disorder.

Using the grip strength effort task to measure reward processing dysfunction in schizophrenia and major depressive disorder.

Journal: Neuroscience applied

Published: December 06, 2024

Exploratory analysis of the relationship between striatal connectivity and apathy during phosphodiesterase 10 inhibition in schizophrenia: findings from a randomized crossover trial.

Exploratory analysis of the relationship between striatal connectivity and apathy during phosphodiesterase 10 inhibition in schizophrenia: findings from a randomized crossover trial.

Journal: BMC medicine

Published: August 08, 2024

The role of biomarkers in clinical development of drugs for neuropsychiatric disorders - A pragmatic guide.

The role of biomarkers in clinical development of drugs for neuropsychiatric disorders - A pragmatic guide.

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Published: April 24, 2024

Negative symptoms in schizophrenia: Newly emerging measurements, pathways, and treatments.

Negative symptoms in schizophrenia: Newly emerging measurements, pathways, and treatments.

Journal: Schizophrenia research

Published: January 04, 2023

Not Mismatch Negativity, but Modulation of Sensory N1 is Measured - Comment to Chen-Engerer et al.

Not Mismatch Negativity, but Modulation of Sensory N1 is Measured - Comment to Chen-Engerer et al.

Journal: Neuroscience

Published: October 06, 2022

Trial of Prasinezumab in Early-Stage Parkinson's Disease.

Trial of Prasinezumab in Early-Stage Parkinson's Disease.

Journal: The New England journal of medicine

Published: August 03, 2022

Showing 1-12 of 54

Last Updated: 09/26/2026